Latest Content

Carl Regillo, MD, explains why wet AMD anti‑VEGF results lag in real life and how newer agents extend dosing, yet the burden persists.

FDA approves Orca-T precision Treg cell therapy for matched donor transplants, cutting chronic GVHD risk and boosting survival in blood cancers.

As CAR T-cell therapy expands into outpatient and community settings, Reimagine Care and The Center for Cancer and Blood Disorders are creating a monitoring infrastructure to support patients and caregivers alike.

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.

This study evaluated whether adherence to a hypertension quality measure correlates with actual blood pressure control. Findings reveal misalignment between adherence metrics and clinical outcomes.

NCCN added pemivibart to its lymphoma guidelines, expanding COVID-19 prevention options for immunocompromised patients.

There was no observed increase in risk to short- or mid-term clinically relevant infections despite the low levels of immunoglobulins.

House lawmakers reviewed veterans' health bills focused on mental health, rural access, spinal injury care, and military aviation research.

Chemo-free zanubrutinib plus rituximab in phase 3 MANGROVE cuts progression/death risk 43% vs BR for frontline mantle cell lymphoma.